Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Sales of the Arena Pharmaceuticals Inc (NASDAQ:ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week’s sales only take us to March 28th, there is enough here for us to assess the sales activity, project some revenue, and look to the pace. Arena Pharmaceuticals, Inc. … Continue reading Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Jason Knox04/0704/07

Biotech Runners: MannKind Corporation (NASDAQ:MNKD), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), CytRx Corporation (NASDAQ:CYTR)

MannKind Corporation (NASDAQ:MNKD) had its price objective reduced by Cowen and Company from $5.50 to $5.00 in a report released on Wednesday,Stock Ratings News reports. Analysts at Piper Jaffray downgraded shares of MannKind Corporation (NASDAQ:MNKD) from a neutral rating to an underweight rating in a research note on Monday. MannKind Corporation (NASDAQ:MNKD) stock performance was -0.86% in last session and finished the day at $6.93. … Continue reading Biotech Runners: MannKind Corporation (NASDAQ:MNKD), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), CytRx Corporation (NASDAQ:CYTR)

Adam Keintzel04/0404/04

Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -3.75% in last session and finished the … Continue reading Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kristen Barton04/0304/03

FB Nasdaq FB Facebook

Diversified Tech

Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Congress jumped into the health care game (again) by “complaining” that Gilead Sciences, Inc. (NASDAQ:GILD)’s hepatitis drug was priced too high. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.92% in last session and finished the day at $73.64. Traded volume was 19.50million shares in the last session and the average volume of the stock remained 13.29million shares. The beta of the stock remained 0.55. Gilead … Continue reading Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Jason Knox04/0204/02

Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Mark DeFrance04/0104/01

Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Merck & Co., Inc. (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. Merck … Continue reading Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kevin Long03/3103/31